Caribou Biociences Q2的结果表明损失高于预期,收入略高。 Caribou Biosciences Q2 results show a better-than-expected loss and slightly higher revenue.

Caribou生物科学公司(CRBU)报告了Q2收入情况,每股0.42美元比预期损失4.46美元,收入为3.46亿美元,略高于3.31亿美元预测。 Caribou Biosciences (CRBU) reported Q2 earnings with a better-than-expected loss of $0.42 per share vs. $0.46 estimate, and $3.46M revenue, slightly higher than $3.31M predictions. 该公司专注于基因组编辑的异构细胞治疗血液恶性瘤,市值为17160万美元,β值为2.30. The company focuses on genome-edited allogeneic cell therapies for hematologic malignancies, with a market cap of $171.60M and a beta of 2.30. 尽管股票收益率和净利率均为负,但股票的交易价格为1.90美元,平均"适度购买"评级和15.00美元的目标价格. Despite negative return on equity and net margin, shares trade at $1.90, with an average "Moderate Buy" rating and $15.00 target price.